Therefore, in the context of renal insufficiency, regulating the FOXO4–ACAA2 axis through CSNO inhalation therapy may provide a novel therapeutic strategy for alleviating myocardial lipid peroxidation and improving cardiac function. This evidence concerns the gene FOXO4 and Renal insufficiency.